DUOS TECHNOLOGIES GROUP INC (DUOT)

US2660424076 - Common Stock

3.07  -0.01 (-0.32%)

Fundamental Rating

2

Taking everything into account, DUOT scores 2 out of 10 in our fundamental rating. DUOT was compared to 276 industry peers in the Software industry. DUOT has a bad profitability rating. Also its financial health evaluation is rather negative. DUOT is valied quite expensively at the moment, while it does show a decent growth rate.



0

1. Profitability

1.1 Basic Checks

In the past year DUOT has reported negative net income.
DUOT had a negative operating cash flow in the past year.
DUOT had negative earnings in each of the past 5 years.
DUOT had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

DUOT has a Return On Assets of -87.51%. This is amonst the worse of the industry: DUOT underperforms 87.96% of its industry peers.
With a Return On Equity value of -209.42%, DUOT is not doing good in the industry: 81.39% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -87.51%
ROE -209.42%
ROIC N/A
ROA(3y)-67.78%
ROA(5y)-70.66%
ROE(3y)-383.12%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

DUOT's Gross Margin of 17.55% is on the low side compared to the rest of the industry. DUOT is outperformed by 85.04% of its industry peers.
In the last couple of years the Gross Margin of DUOT has declined.
The Profit Margin and Operating Margin are not available for DUOT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 17.55%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y80.38%
GM growth 5Y-16.5%

3

2. Health

2.1 Basic Checks

DUOT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, DUOT has more shares outstanding
The number of shares outstanding for DUOT has been increased compared to 5 years ago.
DUOT has a better debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -7.21, we must say that DUOT is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -7.21, DUOT is not doing good in the industry: 87.23% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.01 indicates that DUOT is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.01, DUOT is in the better half of the industry, outperforming 65.33% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -7.21
ROIC/WACCN/A
WACC9.89%

2.3 Liquidity

A Current Ratio of 1.93 indicates that DUOT should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.93, DUOT is in line with its industry, outperforming 56.57% of the companies in the same industry.
DUOT has a Quick Ratio of 1.46. This is a normal value and indicates that DUOT is financially healthy and should not expect problems in meeting its short term obligations.
DUOT has a Quick ratio of 1.46. This is comparable to the rest of the industry: DUOT outperforms 46.35% of its industry peers.
Industry RankSector Rank
Current Ratio 1.93
Quick Ratio 1.46

4

3. Growth

3.1 Past

The earnings per share for DUOT have decreased strongly by -41.44% in the last year.
Looking at the last year, DUOT shows a very negative growth in Revenue. The Revenue has decreased by -50.25% in the last year.
Measured over the past years, DUOT shows a decrease in Revenue. The Revenue has been decreasing by -9.12% on average per year.
EPS 1Y (TTM)-41.44%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-340%
Revenue 1Y (TTM)-50.25%
Revenue growth 3Y-2.42%
Revenue growth 5Y-9.12%
Revenue growth Q2Q-74.27%

3.2 Future

Based on estimates for the next years, DUOT will show a very strong growth in Earnings Per Share. The EPS will grow by 45.05% on average per year.
Based on estimates for the next years, DUOT will show a very strong growth in Revenue. The Revenue will grow by 83.36% on average per year.
EPS Next Y49.97%
EPS Next 2Y45.05%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year98.37%
Revenue Next 2Y83.36%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DUOT. In the last year negative earnings were reported.
Also next year DUOT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as DUOT's earnings are expected to grow with 45.05% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y45.05%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

DUOT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

DUOS TECHNOLOGIES GROUP INC

NASDAQ:DUOT (5/3/2024, 7:00:01 PM)

3.07

-0.01 (-0.32%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap22.44M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -87.51%
ROE -209.42%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 17.55%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.58
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.93
Quick Ratio 1.46
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-41.44%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y49.97%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-50.25%
Revenue growth 3Y-2.42%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y